Dr. Peter D. Higgins, MD, PHD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Duke University School of Medicine (1998)
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 52
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1998Medical school: Duke University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
MI license 4301078119 -
Internal Medicine Physician
MI license 4301078119
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Michigan Health System Ann Arbor, MI
Medical groups
- Regents of the University of Michigan (3,346 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 52
- Services billed
- 93
- Patients’ average age
- 70
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Stelara (ustekinumab) | 32 |
| Xeljanz (tofacitinib citrate) | 24 |
| Azathioprine Other prescribers in Ann Arbor, MI | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 17 payments worth $17,014 in total to this clinician.
| Merck Sharp & Dohme LLC | $8,925 |
|---|---|
| Janssen Biotech, Inc. | $5,269 |
| AbbVie Inc. | $2,800 |
| Abiomed | $20.43 |
| Consulting Fee | $15,620 |
|---|---|
| Travel and Lodging | $819 |
| Food and Beverage | $576 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Jul 1, 2025 | Consulting FeeCompany’s descriptionPayment made to Third Party Organization not to Physician. | $8,320 |
| Janssen Biotech, Inc. Dec 15, 2025 | Consulting Fee TREMFYA · Immunology | $4,500 |
| AbbVie Inc. Jul 1, 2025 | Consulting Fee SKYRIZI · IMMUNOLOGY | $2,100 |
| AbbVie Inc. Jul 1, 2025 | Consulting Fee SKYRIZI · IMMUNOLOGY | $700 |
| Janssen Biotech, Inc. Dec 6, 2025 | Travel and Lodging TREMFYA · Immunology · travel to ORLANDO, FL · in-kind | $381 |
| Janssen Biotech, Inc. Dec 6, 2025 | Travel and Lodging TREMFYA · Immunology · travel to ORLANDO, FL · in-kind | $288 |
| Merck Sharp & Dohme LLC Jun 23, 2025 | Travel and Lodging travel to San Diego, CA Company’s descriptionPayment made to Third Party Organization not to Physician. | $150 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 15 industry-funded studies in 2025, from 3 companies. The companies reported $116,998 in research payments for these studies, mostly to the institutions running them.
- Biometric Predictors of Treatment Failure During Steroid Taper in IBD
AbbVie Inc. - A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intrav…
Takeda Pharmaceuticals U.S.A., Inc. - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
AbbVie Inc. · Active, not recruiting · NCT03105102 - M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433
AbbVie Inc. - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
AbbVie Inc. · Active, not recruiting · NCT03345823 - Entyvio (vedolizumab) long-term safety study: an international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or crohn's disease
Takeda Pharmaceuticals U.S.A., Inc. - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
AbbVie Inc. · Active, not recruiting · NCT03006068 - A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn Disease (CD)
AbbVie Inc. - A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
AbbVie Inc. - M16-000 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.